MXPA05006944A - Conjugados polimericos de interferon-beta cion potencia biologica aumentada. - Google Patents
Conjugados polimericos de interferon-beta cion potencia biologica aumentada.Info
- Publication number
- MXPA05006944A MXPA05006944A MXPA05006944A MXPA05006944A MXPA05006944A MX PA05006944 A MXPA05006944 A MX PA05006944A MX PA05006944 A MXPA05006944 A MX PA05006944A MX PA05006944 A MXPA05006944 A MX PA05006944A MX PA05006944 A MXPA05006944 A MX PA05006944A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- beta
- methods
- interferon
- present
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title abstract 5
- 102000003996 Interferon-beta Human genes 0.000 title abstract 4
- 108090000467 Interferon-beta Proteins 0.000 title abstract 4
- 229960001388 interferon-beta Drugs 0.000 title abstract 4
- 102000004127 Cytokines Human genes 0.000 abstract 4
- 108090000695 Cytokines Proteins 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 108010005716 Interferon beta-1a Proteins 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000010364 biochemical engineering Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229960004461 interferon beta-1a Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/565—IFN-beta
Abstract
Se suministran metodos para la sintesis de conjugados polimericos de citocinas y sus antagonistas de union al receptor, especialmente un interferonbeta no glicosilado, conjugados que retienen una potencia biologica inusualmente elevada. La preparacion de conjugados polimericos de acuerdo con los metodos de la presente invencion reduce o evita la inhibicion esterica de interacciones receptor-ligando que comunmente se producen a partir de la union de polimeros a las regiones de union al receptor de las citocinas, como asi tambien a sus analogos agonistas y antagonistas. La invencion suministra, ademas, conjugados y composiciones producidos por tales metodos. Los conjugados de la presente invencion retienen un elevado nivel de potencia biologica comparados con los producidos por los metodos tradicionales de acoplamiento de polimeros que no se han orientado para evitar los dominios de union al receptor de citocinas. En ensayos in vitro, la potencia biologica de los conjugados de interferon-beta no glicosilado de la presente invencion es sustancialmente mayor que la del interferon-beta no conjugado y es similar a la del interferon-beta-1 que es glicosilado. Los conjugados de la presente invencion muestran ademas mayor vida media in vivo comparados con la correspondiente citoquina no conjugada. La presente invencion suministra, ademas, equipos que comprenden tales conjugados y/o composiciones, y metodos de uso de tales conjugados y composiciones en una variedad de aplicaciones diagnosticas, profilacticas y terapeuticas y de procesamiento biologico incluyendo el tratamiento de la esclerosis multiple.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43602002P | 2002-12-26 | 2002-12-26 | |
US47991303P | 2003-06-20 | 2003-06-20 | |
US47991403P | 2003-06-20 | 2003-06-20 | |
PCT/US2003/041160 WO2004060299A2 (en) | 2002-12-26 | 2003-12-23 | Polymer conjugates of interferon-beta with enhanced biological potency |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05006944A true MXPA05006944A (es) | 2005-12-14 |
Family
ID=32719161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05006944A MXPA05006944A (es) | 2002-12-26 | 2003-12-23 | Conjugados polimericos de interferon-beta cion potencia biologica aumentada. |
Country Status (26)
Country | Link |
---|---|
US (1) | US9125880B2 (es) |
EP (1) | EP1667708B9 (es) |
JP (2) | JP5207590B2 (es) |
KR (1) | KR101238517B1 (es) |
CN (1) | CN102319437B (es) |
AU (1) | AU2003303635B2 (es) |
BR (1) | BR0317742A (es) |
CA (1) | CA2511814C (es) |
CR (1) | CR7894A (es) |
CY (1) | CY1113281T1 (es) |
DK (1) | DK1667708T5 (es) |
EA (1) | EA008866B1 (es) |
EC (1) | ECSP055930A (es) |
ES (1) | ES2389183T3 (es) |
GE (1) | GEP20084486B (es) |
HK (1) | HK1088822A1 (es) |
IL (1) | IL169391A (es) |
IS (1) | IS7932A (es) |
MX (1) | MXPA05006944A (es) |
NO (1) | NO339917B1 (es) |
NZ (1) | NZ541124A (es) |
PL (1) | PL219741B1 (es) |
PT (1) | PT1667708E (es) |
RS (1) | RS20050502A (es) |
TW (1) | TWI406672B (es) |
WO (1) | WO2004060299A2 (es) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
CZ2004877A3 (cs) * | 2002-01-18 | 2004-12-15 | Biogen Idec Ma Inc. | Polymerní sloučeniny na bázi polyalkylenu a jejich použití |
US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
DK2311432T3 (en) | 2002-06-07 | 2015-02-02 | Dyax Corp | Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US9599619B2 (en) | 2002-06-14 | 2017-03-21 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US8821868B2 (en) | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
WO2004060300A2 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
EP1608688B1 (en) | 2003-03-14 | 2013-02-27 | BioGeneriX AG | Branched water-soluble polymers and their conjugates |
MXPA05010411A (es) * | 2003-03-28 | 2006-05-31 | Biopolymed Inc | Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen. |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
CA2525464A1 (en) * | 2003-05-12 | 2004-11-25 | Qun Yin | Novel poly(ethylene glycol) modified compounds and uses thereof |
EA010099B1 (ru) * | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения |
CA2525399A1 (en) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds |
US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
EP1663281B1 (en) * | 2003-08-29 | 2013-12-25 | Dyax Corp. | Poly-pegylated protease inhibitors |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
CA2552892C (en) | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
CA2556339A1 (en) * | 2004-03-01 | 2005-09-15 | David Ray Filpula | Interferon-beta polymer conjugates |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
CA2573113A1 (en) * | 2004-07-26 | 2006-02-09 | Enzon Pharmaceuticals, Inc. | Optimized interferon-beta gene |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
US20090005292A1 (en) * | 2004-11-11 | 2009-01-01 | Affymax, Inc. | Novel Peptides that Bind to the Erythropoietin Receptor |
WO2006074467A2 (en) | 2005-01-10 | 2006-07-13 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
US8067006B2 (en) * | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
CA2627939A1 (en) * | 2005-12-15 | 2007-06-21 | Laboratoires Serono S.A. | New chemokine antagonists |
US20090305947A1 (en) * | 2006-04-11 | 2009-12-10 | Mileutis Ltd | Livestock management for improved reproductive efficiency |
EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
WO2008088658A2 (en) * | 2007-01-17 | 2008-07-24 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
CN101796063B (zh) | 2007-04-03 | 2017-03-22 | 拉蒂奥法姆有限责任公司 | 使用糖聚乙二醇化g‑csf的治疗方法 |
US8114630B2 (en) * | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
EP2170919B8 (en) | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Improved process for the production of nucleotide sugars |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
AU2008289005A1 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
WO2009080699A2 (en) | 2007-12-20 | 2009-07-02 | Merck Serono S.A. | Peg-interferon-beta formulations |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
WO2011091113A2 (en) * | 2010-01-22 | 2011-07-28 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
US20110150820A1 (en) * | 2008-08-28 | 2011-06-23 | Insight Biopharmaceuticals Ltd. | Methods for covalently attaching a polymer to a methionine residue in proteins and peptides |
EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
EP2340045B1 (en) | 2008-09-19 | 2017-04-12 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
DE102009032179A1 (de) * | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
PT3459564T (pt) | 2010-01-06 | 2022-01-31 | Takeda Pharmaceuticals Co | Proteínas de ligação à calicreína plasmática |
AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
WO2012044684A2 (en) * | 2010-10-01 | 2012-04-05 | Biogen Idec Ma Inc. | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
KR101309566B1 (ko) | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 |
EP2661450A4 (en) | 2011-01-06 | 2014-04-23 | Dyax Corp | PROTEINS BINDING TO PLASMA KALLIKREINE |
CN103429263A (zh) | 2011-02-15 | 2013-12-04 | 免疫医疗公司 | 用于胰腺癌早期检测和治疗的抗粘蛋白抗体 |
EP2854845B1 (en) | 2012-06-01 | 2018-03-28 | IBC Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
EP2885002A4 (en) | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9452228B2 (en) | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
US9416197B2 (en) | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
MA40415A (fr) | 2014-09-03 | 2016-03-10 | Immunogen Inc | Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques |
CN107614515B (zh) | 2015-05-28 | 2022-03-22 | 免疫医疗公司 | 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体 |
AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2019032541A1 (en) * | 2017-08-07 | 2019-02-14 | The University Of Akron | POLY (ESTER-UREA) FOR MEMORY OF SHAPE AND ADMINISTRATION OF MEDICINE |
CN109400695B (zh) * | 2018-10-31 | 2020-06-30 | 中南大学湘雅医院 | 一种多肽的修饰方法及应用 |
WO2021236474A1 (en) * | 2020-05-22 | 2021-11-25 | Merck Sharp & Dohme Corp. | Novel processes for preparing conjugates of the il-2 protein |
TW202315940A (zh) * | 2021-10-13 | 2023-04-16 | 芯芮生技開發股份有限公司 | 幹細胞條件培養基於製備抑制癌症組成物的用途 |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
GB1578348A (en) | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
NZ198445A (en) | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4462940A (en) | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
WO1985003934A1 (en) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
JP2524586B2 (ja) * | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4816440A (en) | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
US5037969A (en) | 1986-07-03 | 1991-08-06 | Takeda Chemical Industries, Ltd. | Glycosyl derivatives and use thereof |
US4894330A (en) | 1986-12-23 | 1990-01-16 | Cetus Corporation | Purification of recombinant beta-interferon incorporating RP-HPLC |
US4961969A (en) | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
US5006333A (en) | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
IE64284B1 (en) | 1987-08-03 | 1995-07-26 | Ddi Pharmaceuticals | Conjugates of superoxide dismutase |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5004605A (en) | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US6132763A (en) | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5091176A (en) | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
ATE163431T1 (de) | 1990-05-04 | 1998-03-15 | American Cyanamid Co | Stabilisierung von somatotropin durch modifizierung von cysteinsresten |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
EP0576589A4 (en) | 1991-03-18 | 1994-07-27 | Enzon Inc | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
US5221676A (en) * | 1992-02-06 | 1993-06-22 | Warner-Lambert Company | 7-substituted quinolones and naphthyridones as antibacterial agents |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
ES2174915T3 (es) | 1993-11-10 | 2002-11-16 | Enzon Inc | Productos de conjugacion mejorados de un interferon con un polimero. |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
EP0755263A4 (en) | 1994-03-31 | 2005-02-09 | Amgen Inc | COMPOUNDS AND METHODS FOR STIMULATING MEGAKARYOCYTE GROWTH AND THEIR DIFFERENTIATION |
US5889153A (en) | 1994-05-20 | 1999-03-30 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, method for producing the same and intermediate compound therefor |
EP0756494A1 (en) | 1994-05-24 | 1997-02-05 | Amgen Boulder Inc. | Modified insulin-like growth factors |
US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US20030053982A1 (en) | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5756593A (en) | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
WO1996040731A1 (en) | 1995-06-07 | 1996-12-19 | Mount Sinai School Of Medicine Of The City University Of New York | Pegylated modified proteins |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
JP4410852B2 (ja) | 1996-08-02 | 2010-02-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 単一の共有結合n末端水溶性ポリマーを有するポリペプチド |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
JP2001510033A (ja) | 1997-07-14 | 2001-07-31 | ボルダー バイオテクノロジー, インコーポレイテッド | 成長ホルモンおよび関連タンパク質の誘導体 |
US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
DE69921102T2 (de) | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
DE69929311T2 (de) | 1998-03-24 | 2006-09-07 | Nof Corp. | Oximanderivate und verfahren zu ihrer herstellung |
IL139286A (en) | 1998-04-28 | 2005-12-18 | Applied Research Systems | Polyol-ifn-beta conjugates, their preparation and use |
EP1079851B1 (en) | 1998-05-12 | 2007-07-04 | Greenville Hospital System | Use of anti-prolactin agents to treat cancer |
CA2338665C (en) | 1998-08-06 | 2011-01-18 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
SG110047A1 (en) | 1998-10-16 | 2005-04-28 | Biogen Inc | Polymer conjugates of interferon beta-a1 and uses |
AU775937B2 (en) | 1999-01-14 | 2004-08-19 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
KR20020034181A (ko) | 1999-08-27 | 2002-05-08 | 맥시겐 에이피에스 | 새로운 인터페론 베타-유사 분자 |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
EP1270642B1 (en) | 1999-12-24 | 2011-08-31 | Kyowa Hakko Kirin Co., Ltd. | Branched polyalkylene glycols |
IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
AU2002216749A1 (en) | 2000-06-30 | 2002-01-14 | Smithkline Beecham Corporation | Chemokine conjugates |
DE60137525D1 (de) | 2000-10-16 | 2009-03-12 | Chugai Pharmaceutical Co Ltd | Peg-modifiziertes erythropoietin |
WO2002049673A2 (en) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
JP2005502591A (ja) * | 2001-01-12 | 2005-01-27 | カイロン コーポレイション | 核酸粘膜免疫 |
EP2080771A3 (en) * | 2001-02-27 | 2010-01-06 | Maxygen Aps | New interferon beta-like molecules |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
JP2004522803A (ja) | 2001-06-29 | 2004-07-29 | マキシゲン・エイピーエス | インターフェロン製剤 |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
WO2003049760A1 (en) | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
WO2003049699A2 (en) | 2001-12-11 | 2003-06-19 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
CZ2004877A3 (cs) * | 2002-01-18 | 2004-12-15 | Biogen Idec Ma Inc. | Polymerní sloučeniny na bázi polyalkylenu a jejich použití |
AU2003256613A1 (en) | 2002-07-19 | 2004-02-09 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
AU2003254641A1 (en) | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
BR0314172A (pt) * | 2002-09-09 | 2005-07-26 | Nektar Therapeutics Al Corp | Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
CA2504267A1 (en) | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
US8828373B2 (en) | 2002-11-20 | 2014-09-09 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
US20040142870A1 (en) | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
TWI281864B (en) | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
WO2004060300A2 (en) | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
US7587286B2 (en) | 2003-03-31 | 2009-09-08 | Xencor, Inc. | Methods for rational pegylation of proteins |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
CA2556339A1 (en) | 2004-03-01 | 2005-09-15 | David Ray Filpula | Interferon-beta polymer conjugates |
RU2298560C2 (ru) | 2004-04-30 | 2007-05-10 | Открытое Акционерное Общество "Верофарм" | Конъюгаты белка и производного полиэтиленгликоля, фармацевтическая композиция, способ борьбы с вирусной инфекцией |
AU2006332533A1 (en) | 2005-12-30 | 2007-07-12 | Pharmaessentia Corp. | Drug-polymer conjugates |
-
2003
- 2003-12-23 ES ES03808554T patent/ES2389183T3/es not_active Expired - Lifetime
- 2003-12-23 DK DK03808554T patent/DK1667708T5/da active
- 2003-12-23 EA EA200501050A patent/EA008866B1/ru not_active IP Right Cessation
- 2003-12-23 RS YUP20050502 patent/RS20050502A/sr unknown
- 2003-12-23 GE GEAP2003008910 patent/GEP20084486B/en unknown
- 2003-12-23 PL PL379987A patent/PL219741B1/pl unknown
- 2003-12-23 MX MXPA05006944A patent/MXPA05006944A/es active IP Right Grant
- 2003-12-23 BR BR0317742A patent/BR0317742A/pt not_active Application Discontinuation
- 2003-12-23 NZ NZ541124A patent/NZ541124A/en not_active IP Right Cessation
- 2003-12-23 CA CA 2511814 patent/CA2511814C/en not_active Expired - Fee Related
- 2003-12-23 WO PCT/US2003/041160 patent/WO2004060299A2/en active Search and Examination
- 2003-12-23 KR KR20057012126A patent/KR101238517B1/ko active IP Right Grant
- 2003-12-23 US US10/743,068 patent/US9125880B2/en not_active Expired - Fee Related
- 2003-12-23 JP JP2005508613A patent/JP5207590B2/ja not_active Expired - Fee Related
- 2003-12-23 AU AU2003303635A patent/AU2003303635B2/en not_active Ceased
- 2003-12-23 CN CN201110224336.2A patent/CN102319437B/zh not_active Expired - Fee Related
- 2003-12-23 PT PT03808554T patent/PT1667708E/pt unknown
- 2003-12-23 TW TW92136583A patent/TWI406672B/zh not_active IP Right Cessation
- 2003-12-23 EP EP20030808554 patent/EP1667708B9/en not_active Revoked
-
2005
- 2005-06-26 IL IL169391A patent/IL169391A/en active IP Right Grant
- 2005-07-04 CR CR7894A patent/CR7894A/es unknown
- 2005-07-04 IS IS7932A patent/IS7932A/is unknown
- 2005-07-20 NO NO20053556A patent/NO339917B1/no not_active IP Right Cessation
- 2005-07-20 EC ECSP055930 patent/ECSP055930A/es unknown
-
2006
- 2006-08-21 HK HK06109227A patent/HK1088822A1/xx not_active IP Right Cessation
-
2012
- 2012-06-20 JP JP2012138434A patent/JP2012232984A/ja not_active Withdrawn
- 2012-09-05 CY CY20121100796T patent/CY1113281T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05006944A (es) | Conjugados polimericos de interferon-beta cion potencia biologica aumentada. | |
TW200501979A (en) | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity | |
GB0317815D0 (en) | Imaging agents | |
MA28182A1 (fr) | Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues | |
EP2327593A3 (en) | Compositions containing fluorine substituted olefins | |
HK1091486A1 (en) | Quinazoline derivatives | |
EP2287282A3 (en) | Compositions containing fluorine substituted olefins | |
SE9902987D0 (sv) | Novel compounds | |
PL366198A1 (en) | Novel compounds | |
MXPA02006029A (es) | Lipopeptidos novedosos como agentes antibacterianos. | |
HK1048990A1 (en) | Novel compounds. | |
SE0103836D0 (sv) | Novel compounds | |
EP0966456A4 (en) | THE ACTIVE SUBSTANCE RESISTANCE IN CANCER CHEMOTHERAPY REVERSING TAXOIDS AND PHARMACEUTICAL PREPARATIONS THEREOF | |
SE0302139D0 (sv) | Novel compounds | |
EP1755388A4 (en) | MIXED CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | |
TW200604197A (en) | New compounds | |
SE0101038D0 (sv) | Novel compounds | |
GB0120461D0 (en) | Novel compounds | |
SE0303280D0 (sv) | Novel compounds | |
ATE409045T1 (de) | Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib | |
MXPA04005151A (es) | Compuestos terapeuticos. | |
EP1514855A3 (en) | Hydraulic composition having high fluidity | |
AR073408A2 (es) | Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |